Verified against court and regulatory records · No upfront fees · Your information is never sold
Quick Eligibility Review
Answer one question at a time. This usually takes under 2 minutes.
Check your eligibility — free
Answer 2-3 quick questions to review your potential case.
Free · Confidential · About 2 minutes · A case specialist responds within 1 business day
Your answers are never sold or shared without your consent.
While AndroGel and AbbVie dominate media coverage of TRT litigation, two other major products — Axiron (Eli Lilly) and Androderm (Actavis/Allergan, now Teva Pharmaceuticals) — remain in active MDL 2545 litigation. Eli Lilly marketed Axiron as an axillary (underarm) testosterone gel from 2011 through approximately 2019. Actavis's Androderm transdermal patch held the second-largest market share in the TRT category throughout the peak marketing period.
Neither Eli Lilly nor Actavis/Teva has completed global settlement of their MDL 2545 dockets as of early 2026. This means men who used Axiron or Androderm and suffered cardiovascular injuries are still in the active litigation phase — not the post-settlement distribution phase. Settlement discussions for these defendants were reported in 2024–2025. If you used Axiron or Androderm and have not yet filed, time remains available but is narrowing as settlement frameworks take shape.
The full investigation